Table of Contents Table of Contents
Previous Page  301 / 812 Next Page
Information
Show Menu
Previous Page 301 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

S297

Conclusions

In this young, newly diagnosed schizophrenia pop-

ulation, the number of hospitalizations following PP initiation was

low. Main reason to initiate PP was clinicians favoring LAT over

oral antipsychotic treatment for relapse prevention or due to par-

tial/non adherence with previous oral treatment.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.637

EW520

Real-world paliperidone palmitate

data from acute units: The SHADOW

study

E. Parellada

1 ,

, M. Bioque

1

, B. Herrera

2

, M. García-Dorado

2

1

Hospital Clínic de Barcelona, Unitat d’Esquizofrènia Clínic,

Barcelona, Spain

2

Janssen-Cilag S.A., Medical Department, Spain

Corresponding author.

Introduction

There is an increasing interest in understanding

how antipsychotic treatments work in a real-world-setting. This

is especially important with long-acting-antipsychotics, where

explanatory trials may not always represent the real-world-

population. Observational studies and pragmatic-clinical trials

could provide additional information about new therapies, which

could inform decision-making processes.

Objectives

To assess the effectiveness of Paliperidone-

Palmitate(PP) in an acute setting within real-world-conditions.

Functionality, satisfaction with treatment and pattern of use were

also evaluated.

Methods

An observational, prospective 6-week follow-up study

was performed in acute units including adult patients with acute

exacerbation of schizophrenia that started treatment with PP. Data

were collected from initiation of PP until week-6 (or patient’s dis-

charge if earlier). Clinical-Global Inventory-Severity (CGI-S) was

used to assess effectiveness as well as changes in illness severity.

Other outcomes included total score on the Personal and Social Per-

formance scale (PSP), patient-satisfaction with medication (MSQ)

and tolerability. Student’s-

t

tests were used to assess changes from

baseline in CGI-S and PSP.

Results

Two hundred and eighty patients were included in the

analysis (mean age: 40.5

±

12.2 [SD] years). A significant decrease

in mean (SD) CGI-S score between baseline (4.7 [0.9]) and end-

point (3.3 [0.9]) (

P

< 0.0001) was observed. (Note that 21% of

patientswere dischargedonPP-monotherapy). Patient-functioning

also significantly improved from baseline to endpoint (

P

< 0.0001).

Seventy-four percent of patients were satisfied (measured by

MSQ) at the end of follow-up. Anticholinergic-treatment was less

frequent for PP discharged on monotherapy vs. not monother-

apy (12.5% vs 21.2% respectively). Overall, PP was well-tolerated.

Twenty-five AEs were reported in 20 patients (incidence 7.1%). No

serious AEs occurred.

Conclusions

These results support the effectiveness and tolera-

bility of PP in an acute setting under daily-clinical-practice with

good acceptance by patients.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.638

EW521

Reducing cardiovascular risk in

non-selected outpatients with

schizophrenia: A 2.5-year programme

conducted in a real-life setting

P. Hjorth

1 ,

, P.M. Jørgensen

2

, A. Kynde

3

1

Aarhus university hospital, mental health center- psychiatric

hospital, Randers, Denmark

2

Odense university hospital, department of psychiatry, Odense,

Denmark

3

Aarhus university hospital- Risskov, department of organic mental

disorder and emergency Ward, Aarhus, Denmark

Corresponding author.

Introduction

Patients with schizophrenia have increased somatic

morbidity and increased mortality. Knowledge of how to integrate

prevention and care of somatic illnesses into the treatment of psy-

chiatric patients is required.

Objectives

Forty-seven patients diagnosed with schizophrenia

participated in the programme (mean age: 33.3 years, SD: 11.9).

Aims

To investigate whether a 2.5-year interventional pro-

gramme to improve physical health is effective.

Method

The intervention consistedof healthpromotion activities

focusing on the patients’ health, not their diseases. The patients’

physical health parameters were intensely monitored and each

patient received individual guidance on healthy food and on how

to live a physically active life.

Results

Extensive problems with obesity, especially among the

women, were observed, and low level of physical activity among

the patients was demonstrated. The included patients were in a

high risk of developing cardio vascular diseases and diabetes type 2.

The main outcomes were reduction in waist circumferences and in

consumption of soft drinks and an increase in coffee drinking. Fur-

thermore, an increase in time spent on moderate and light physical

activities was observed. The patients showed great interest in the

programme, and it was unproblematic getting the patients to par-

ticipate in the entire programme. Moreover, theywillingly followed

the health guidance and achieved a healthier life.

Conclusions

The intervention seems relevant and manageable

in an outpatient setting. The results are promising in the ongo-

ing process of improving physical health among patients with

schizophrenia. We recommend implementation of the programme

in daily practice.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.639

EW522

A mirror image study of the utility of

long acting aripiprazole

R. Hodgson

, C. A

ladakatti , N. Kataria , T. Saravanappa ,

D. Brittany

Lyme Brook Centre, Psychiatry, Stoke-on-Trent, United Kingdom

Corresponding author.

Aims and background

Ablify Maintena (AM) is a long acting injec-

tion of aripiprazole that receivedmarketing authorisation in the UK

in January 2014. It is costly compared to first generation antipsy-

chotics (FGAs) LAIs and there are no robust trials comparing AM

with FGAs. We examined the effectiveness and use of AM in a

mental health trust.

Methods

We identified all patients prescribed AM in North

Staffordshire (population: 470,000) since launch and examined

records for demography, diagnosis, bed and medication use. We

examined the effectiveness of AM using a mirror image design.

Results

Thirty patients received AM in a time frame allowing a 1-

year follow-up. Sixty-nine percentweremale and themean agewas

39 years. Over half were detained under the 1983 Mental Health

Act and 30% were inpatients on a psychiatric intensive care unit

when AMwas started. Twenty-eight patients had a psychotic diag-

nosis. There was a significant reduction in bed occupancy (63 v 6

days,

P

= 0.0001) and admissions (1.6 v 0.5,

P

= 0.0001). The median

dose was 400 mg. Lack of effectiveness/poor adherence with prior

treatments were the main reason for starting AM in 84%. Eighty-six